Growth of the Automated Cell Counters Market

The automated cell counters market is projected to expand from US$ 6,974.29 million in 2021 to US$ 10,365.95 million by 2028, reflecting a compound annual growth rate (CAGR) of 5.9% from 2022 to 2028.

Market Trends and Growth Drivers

This report outlines the prevailing trends and factors propelling market growth. A significant driver of this expansion is the increasing incidence of both infectious and chronic diseases. Furthermore, advancements in automated cell counting technology are anticipated to be a key trend influencing the market during the forecast period. However, challenges such as a shortage of skilled professionals and the high costs associated with these instruments may impede market growth.

Chronic Diseases Overview

Chronic diseases are long-lasting conditions that require ongoing medical attention and can limit daily activities. They are currently the leading cause of mortality among adults in numerous countries. According to the World Health Organization (WHO), approximately 41 million people die each year from chronic diseases, accounting for 71% of all global deaths. The Centers for Disease Control and Prevention (CDC) reports that six out of ten adults in the United States have a chronic disease, with four in ten adults suffering from two or more chronic conditions. In 2018, Cancer Research UK noted that around 17 million new cancer cases were diagnosed worldwide, leading to approximately 9.6 million cancer-related deaths that same year.

Infectious Diseases Impact

Infectious diseases arise from pathogens such as viruses, bacteria, parasites, and fungi. HIV remains a significant global health concern, with the Joint United Nations Programme on HIV/AIDS (UNAIDS) reporting that about 37.7 million individuals were living with HIV in 2020, including 1.7 million children aged 0-14. Additionally, hepatitis, which inflames the liver due to viral infections, affects approximately 58 million people with chronic hepatitis C, with 1.5 million new infections occurring annually, according to WHO.

Moreover, tuberculosis (TB) ranks as the thirteenth leading cause of death globally and the second most deadly infectious disease after COVID-19. In 2020, TB was responsible for 1.5 million deaths, including 214,000 individuals co-infected with HIV. The WHO estimated that 10 million people had TB in 2020, with significant cases concentrated in high-burden countries such as India, China, and the Philippines.

Role of Diagnostics in Disease Management

Diagnostics play a crucial role in guiding treatment for infectious and chronic diseases. Cell counting is a vital method for detecting these conditions, thus driving the demand for automated cell counters in the market.

Challenges Facing Market Growth

Despite the growth potential, the automated cell counters market faces challenges, particularly the shortage of skilled personnel and the high costs of instruments. The WHO has highlighted a significant gap in healthcare professionals trained to operate automated cell counters. The complexity of these devices necessitates a skilled workforce, as improper handling can lead to increased costs and inefficiencies. The price range for automated cell counters is between US$ 3,000 and US$ 6,000, and additional costs for accessories and consumables can further escalate expenses. Maintenance and potential damage to the equipment also contribute to the overall financial burden, limiting market growth.

Market Segmentation

The automated cell counters market is categorized by type into hematocytometers, flow cytometers, electrical impedance coulter counters, and spectrophotometers. In 2021, the spectrophotometers segment dominated the market share, while the hemocytometers segment is projected to experience the highest CAGR from 2022 to 2028. By end user, the market is divided into hospitals, research laboratories, diagnostic centers, and others, with hospitals holding the largest market share in 2021. However, research laboratories are expected to show the highest growth rate during the forecast period.

Strategic Developments in the Market

Companies in the automated cell counters market are employing various organic and inorganic strategies to enhance their market presence. Organic strategies include product launches and approvals, while inorganic strategies involve acquisitions, collaborations, and partnerships. These strategies enable companies to broaden their business scope and improve their geographic reach, contributing to overall market growth. For instance, in April 2021, Eppendorf launched the "Centrifuge 5910 Ri," aimed at enhancing laboratory efficiency, succeeding the popular Centrifuge 5910 R.

Conclusion

In summary, the automated cell counters market is poised for significant growth driven by the rising prevalence of chronic and infectious diseases, despite facing challenges such as high costs and a lack of skilled professionals. Ongoing advancements in technology and strategic initiatives by key players will likely shape the future landscape of this market.

Key sources for this report include the Centers for Disease Control and Prevention (CDC), Infectious Disease Research Institute (IDRI), Saudi Society for Blood Disorders (SSBD), Saudi Commission for Health Specialties (SCFHS), National Institute of Allergy and Infectious Disease (NIAID), and the Australian Federation of AIDS Organizations (AFAO).